-

Corsera Health Named a 2026 “Endpoints 11” Honoree

BOSTON--(BUSINESS WIRE)--Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced that it has been named to the 2026 “Endpoints 11” list of the most promising startups in the biopharmaceutical industry. The annual Endpoints News honor recognizes private companies that are pursuing the most ambitious scientific breakthroughs of tomorrow, backed by expert leadership and strong investor confidence.

“At Corsera Health, we have a bold vision: a world without cardiovascular disease,” said John Maraganore, Ph.D., Co-Founder and Co-CEO. “We are pursuing this vision by combining early prediction of lifetime cardiovascular disease risk through Klotho, our proprietary AI-powered platform, with preventive medicines designed to address the major drivers of cardiovascular disease. Our first preventive RNAi medicine is advancing through Phase 1 clinical development, marking important progress toward bringing prediction and prevention together to advance a new approach to cardiovascular health.”

“Cardiovascular disease remains the leading cause of death worldwide, yet too often, current medical practice addresses its major risk factors only after years of cumulative exposure,” said Clive Meanwell, M.B., Ch.B., M.D., Co-Founder and Co-CEO. “Our goal is to change that paradigm by identifying cardiovascular risk earlier and intervening before disease develops. We are grateful to Endpoints News for recognizing the work of the Corsera Health team and the potential of our approach to change the trajectory of cardiovascular disease and extend healthspan on a global scale.”

Corsera Health was recognized alongside the other 2026 Endpoints 11 honorees at an awards gala held in Boston on September 24, 2026.

About Corsera Health

Corsera Health aims to lead the future of medicine by extending healthspan through cardiovascular disease prediction and prevention. Co-founded by industry pioneers in RNAi therapeutics and cardiovascular medicine, the company is combining decades of innovation in RNAi therapeutics with world-leading expertise in cardiovascular disease prediction, efficient manufacturing and evidence generation, and disruptive commercialization. Corsera Health is headquartered in Boston, Mass. For more information, please visit us at www.corserahealth.com and follow us on LinkedIn and X.

About Endpoints

Endpoints News is the biopharma industry’s trusted news authority. As part of the Financial Times’ FT Specialist group, Endpoints publishes daily newsletters, delivers award-winning reporting on its website, hosts industry-leading events and builds products connecting and informing sophisticated business audiences. For more information, visit www.endpts.com.

Contacts

Media:
Katie Engleman
katie@1abmedia.com

Investors:
Meredith Kaya
meredith@corsera.com

Corsera Health, Inc.


Release Versions

Contacts

Media:
Katie Engleman
katie@1abmedia.com

Investors:
Meredith Kaya
meredith@corsera.com

More News From Corsera Health, Inc.

Corsera Health Initiates Phase 1 Trial of COR-1004 and COR-2003, a Novel Dual-Targeting RNAi Medicine to Prevent Cardiovascular Disease

BOSTON--(BUSINESS WIRE)--Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced today that it has initiated a Phase 1 trial of COR-1004 and COR-2003 in Australia and New Zealand. The trial will evaluate COR-2003 alone as well as the co-administration of COR-1004 and COR-2003, marking the first clinical evaluation of this dual-targeting approach for the prevention of cardiovascular disease. COR-1004 is a novel inves...

Corsera Health Announces $80 Million Series A Financing and Reaches Key Clinical Milestone

BOSTON--(BUSINESS WIRE)--Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced it has raised $80 million in a Series A financing. Forbion and Population Health Partners co-led the oversubscribed Series A which included participation from other leading investors, including Corsera Co-Founder and Co-CEO John Maraganore, Ph.D. In connection with the Series A financing, Marco Boorsma, Ph.D., General Partner at Forbion...

Corsera Health Files First Phase 1 Clinical Trial Application for its Lead Preventive RNAi Medicine Program for Cardiovascular Disease

BOSTON--(BUSINESS WIRE)--Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification (CTN) to initiate a Phase 1 clinical trial of COR-1004 in New Zealand. COR-1004 is a novel investigational subcutaneously administered RNAi medicine targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), which controls low-density lipoprotein cholesterol (LDL-C) levels in the blood. COR-1004 is the fir...
Back to Newsroom